Human IL-13 / IL-13 R alpha 1 Inhibitor Screening Kit (TR-FRET)

ユーザーレビュー
製品番号/仕様
価格
数量
FRT-P038-100tests
$770.00
FRT-P038-500tests
$2080.00
ETA of in-stock products:2 business days
総アイテム数 製品金額$ 0

製品詳細

  • FAB

    1. Comprehensive validation - Validated with various antibody drugs.
    2. Simple and fast operation - No complicated washing steps, significantly reducing time.
    3. High batch consistency - Strict control over raw materials and finished product quality, ensuring a stable supply.
    4. Accurate and reliable results - High sensitivity with minimal matrix effects.
    5. High throughput capability - Support multiple product specifications, ideal for high-throughput screening.
    6. Fast completion - Results in just 1 hour.
  • Product Specifications

    Assay Type
    Competition-TR-FRET
    Reactivity
    Human
    Regulatory Status
    RUO
    Assay Time
    1 hr
    Sample volume
    10 μL

  • Product Overview

    The Human IL-13 / IL-13 R alpha 1 Inhibitor Screening Kit (TR-FRET) is based on a homogeneous (no wash) competition TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer) to screen for inhibitors of human IL-13 binding to IL-13 R alpha 1 within one hour. It can also be used as a universal detection tool to identify the ability of human IL-13 to bind to human IL-13 R alpha 1.

  • Storage

    1. Store the unopened kit at 2-8°C upon receipt.

    2. Locate the expiration date on the outer packaging and do not use reagents beyond their expiration date.

    3. The opened kit should be stored according to the storage conditions listed in the Components Table. The shelf life of the opened kit is 30 days from the date of opening.

  • Materials Provided

    ID
    Components
    Size
    FRTP038-C01
    Human IL-13 Protein Europium-chelate
    100 tests/500 tests
    FRTP038-C02
    FA-Labeled Human IL-13 R alpha 1 Protein
    100 tests/500 tests
    FRTP038-C03
    Anti-IL-13 Antibody
    30 μg/100 tests 150 μg/500 tests
    DB-04
    TR-FRET Sample Dilution Buffer, pH7.4
    50 mL/100 tests & 500 tests
    DB-05
    TR-FRET Detection Buffer, pH7.4
    50 mL/100 tests & 500 tests

  • Assay Principles

    This Human IL-13 / IL-13 R alpha 1 Inhibitor Screening Kit (TR-FRET) is based on TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer). This assay uses the mixture of biotinylated human IL-13 and Europium-chelate labeled streptavidin as the Donor and FA-Labeled Human IL-13 R alpha 1 Protein as the Acceptor.

    — When the sample does not contain the inhibitors that block the binding of human IL-13 to human IL-13 R alpha 1, the Donor and Acceptor are in close proximity because of the binding of human IL-13 and human IL-13 R alpha 1. Upon Donor excitation with light of a specific wavelength (337 nm), in addition to Donor emission (620 nm), non-radiative transfer of energy occurs between Donor and Acceptor, resulting in Acceptor emission (665 nm).

    — When the sample contains the inhibitors that block the binding of human IL-13 to human IL-13 R alpha 1, the components inhibit the binding between the Donor and Acceptor and thereby prevent FRET from occurring.

    Assay Principles
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

お客様はこちらも閲覧

データ表示

  • Bioactivity-TR-FRET 

    Please refer to DS document for the assay protocol.

     IL-13 TR-FRET

    In this TR-FRET assay, Human IL-13 Protein Europium-chelate is used as the Donor and FA-Labeled Human IL-13 R alpha 1 Protein is used as the Acceptor. An inhibition Assay was performed to evaluate the interaction between human IL-13 and human IL-13 R alpha 1 using Anti-IL-13 Antibody resulting in a typical IC50 of 0.633 nM (QC tested).

  •  IL-13 TR-FRET

    The kit is suitable for the detection and characterization of human IL-13 / IL-13 R alpha 1 inhibitors. It was shown that the anti-IL-13 (Tralokinumab) and anti-IL-13 (Lebrikizumab) disrupted the interaction, with an IC50 of 0.7826 & 1.464 nM. The anti-TNF-alpha (Adalimumab) showed no significant inhibitory effect in the assay as expected.

ユーザーレビュー
コメントを投稿

最新の進展

 
医薬品開発の進捗
  • 英語名:

    Interleukin-13

  • カテゴリ:

  • 市販の医薬品数:

    4 詳細

  • 治験医薬品数:

    27 詳細

  • 最新の開発ステージ:

    Approved

お問い合わせ
医薬品候補ライセンス
他の関連情報
  • 製品情報
  • 製品詳細
  • お客様はこちらも閲覧
  • データ表示
  • ユーザーレビュー
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8